Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Glaukos Corporation GKOS
$59.07
+$0.17 (0.29%)
На 18:00, 12 мая 2023
-0.68%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2850580431.00000000
-
week52high
60.92
-
week52low
35.75
-
Revenue
282862000
-
P/E TTM
-26
-
Beta
1.24325200
-
EPS
-2.09000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Stifel | Buy | Hold | 12 июл 2022 г. |
| Citigroup | Neutral | Neutral | 17 мая 2022 г. |
| Citigroup | Neutral | Neutral | 23 февр 2022 г. |
| William Blair | Outperform | Market Perform | 03 февр 2022 г. |
| Wells Fargo | Equal-Weight | Underweight | 19 янв 2022 г. |
| Needham | Buy | 04 окт 2022 г. | |
| Piper Sandler | Neutral | Neutral | 03 ноя 2022 г. |
| Needham | Buy | Buy | 03 ноя 2022 г. |
| JP Morgan | Underweight | Underweight | 03 ноя 2022 г. |
| Stephens & Co. | Overweight | Overweight | 28 дек 2022 г. |
| Mizuho | Neutral | 22 дек 2022 г. | |
| JP Morgan | Neutral | Underweight | 19 дек 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 12 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Burns Thomas William | D | 679062 | 721 | 26 янв 2023 г. |
| Burns Thomas William | D | 679783 | 1802 | 26 янв 2023 г. |
| Navratil Tomas | D | 41008 | 356 | 26 янв 2023 г. |
| Navratil Tomas | D | 41364 | 885 | 26 янв 2023 г. |
| Navratil Tomas | D | 42249 | 389 | 11 янв 2023 г. |
| Navratil Tomas | D | 42638 | 1299 | 11 янв 2023 г. |
| Gilliam Joseph E | D | 104374 | 159 | 11 янв 2023 г. |
| Gilliam Joseph E | D | 104533 | 795 | 11 янв 2023 г. |
| Burns Thomas William | D | 681585 | 326 | 11 янв 2023 г. |
| Burns Thomas William | D | 681911 | 2794 | 11 янв 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2496380 | 13201 | 31 авг 2020 г. |
| Vanguard Total Stock Market Index Fund | 1183480 | 483 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 907481 | 25992 | 31 авг 2020 г. |
| Vanguard Small-Cap Index Fund | 1042980 | -10260 | 31 июл 2020 г. |
| Brown Capital Management Small Company Fund | 2460620 | 0 | 30 июн 2020 г. |
| Vanguard U.S. Growth Fund | 1208560 | 0 | 30 июн 2020 г. |
| Baillie Gifford American Fund | 1208300 | 62965 | 30 июн 2020 г. |
| American Funds SMALLCAP World Fund | 1150320 | 0 | 30 июн 2020 г. |
| Ivy Mid Cap Growth Fund | 858919 | 0 | 30 июн 2020 г. |
| Janus Henderson Triton Fund | 1417070 | -178855 | 31 мар 2020 г. |
Новостная лента
Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y
Zacks Investment Research
04 мая 2023 г. в 08:22
Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.
Glaukos Corporation (GKOS) Q1 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 22:53
Glaukos Corporation (NYSE:GKOS ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns – Chairman and Chief Executive Officer Joe Gilliam – President and Chief Operating Officer Alex Thurman – Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Ryan Zimmerman – BTIG George Sellers – Stephens Allen Gong – JP Morgan Anthony Petrone – Mizuho Group Operator Welcome to Glaukos Corporation's First Quarter 2023 Financial Results Conference Call. Copies of the company's press release and quarterly summary document will be issued after the market close today are available at www.glaukos.com.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 20:32
Glaukos (GKOS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.38 per share a year ago.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
Zacks Investment Research
03 апр 2023 г. в 12:55
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
Zacks Investment Research
28 дек 2022 г. в 12:21
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.